Last updated: April 2, 2024
Sponsor: University Hospital, Gentofte, Copenhagen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Metabolic Disorders
Treatment
Placebo
Oxytocin
Clinical Study ID
NCT06334172
H-23071221
Ages 20-50 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- BMI 19-25 kg/m2
Exclusion
Exclusion Criteria:
- Diabetes
- Heart-, liver or kidney disease
- More than 14 units of alcohol weekly, or drug abuse
- Smoking or any kind of nicotine products
- Alanin aminotransferase (ALAT) ≥ 2 × normal range
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1,73m2 or creatinine abovenormal range
- Blood pressure > 140/90
- Hemoglobin < normal range
- Corrected QT Interval (Qtc) >0,45 sec. at electrocardiogram (ECG) at screening
- Known disease in the pituitary gland or previous pituitary surgery
- Any other disease/condition which the trial managers believe may affect participationin the trial
Study Design
Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region 2900
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.